


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
19781

In Re Application Of: **Angeline Ingrid Bartholomeusz, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,906	April 21, 2006	Unassigned	23389	1645	7415

Title: **HBV VARIANTS DETECTION AND APPLICATION**



Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))


Docket No.  
19781

In Re Application of: **Angeline Ingrid Bartholomeusz, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,906	April 21, 2006	Unassigned	23389	1645	7415

Title:

**OBVIOUSLY DETECTION AND APPLICATION**



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to \*Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450\* [37 CFR 1.8(a)] on

April 12, 2007  
(Date)

Xiaochun Zhu  
Signature of Person Mailing Correspondence

Xiaochun Zhu

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Xiaochun Zhu  
Signature

Dated: **April 12, 2007**

**Xiaochun Zhu**  
Registration No. 56,311  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Angeline Ingrid Bartholomeusz, et al. **Examiner:** Unassigned  
**Serial No.:** 10/576,906 **Art Unit:** 1645  
**Filed:** April 21, 2006 **Docket:** 19781  
**For:** HBV VARIANTS DETECTION **Dated:** April 12, 2007  
AND APPLICATION

**Confirmation No.:** 7415

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Chen W.N. et al., "Human Hepatitis B Virus Mutants: Significance of Molecular Changes", *FEBS Letters* 453(3):237-242 (1999), XP004259880;
2. Stuyver L.J. et al., "Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region", *Hepatology* 33(3):751-757 (2001), XP009029630;
3. PCT International Publication No. WO 01/94559 A1, published December 13, 2001;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 12, 2007

  
Xiaochun Zhu

4. Bartholomew M.M. et al., "Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection After Orthotopic Liver Transplant Ation", *Lancet* 349(9044):20-22 (1997), XP004843545;
5. Bartholomeusz A. et al., "Mutations in the Hepatitis B Virus Polymerase Gene that are Associated with Resistance to Famciclovir and Lamivudine", *International Antiviral News* 5(8):123-124 (1997), XP002044248;
6. Alestig E. et al., "Phylogenetic Origin of Hepatitis B Virus Strains with Precore C-1858 Variant", *Journal of Clinical Microbiology* 39(9):3200-3203 (2001), XP002419805; and
7. Günther S. et al., "Analysis of Hepatitis B Virus Populations in an Interferon- $\alpha$ -Treated Patient Reveals Predominant Mutations in the C-Gene and Changing e-Antigenicity", *Virology* 244(1):146-160 (1998), XP004845022.

References 1-3 were cited in a Supplementary Partial Search Report dated December 12, 2006 received from the European Patent Office. References 1-7 were cited in a Supplementary Partial Search Report dated February 26, 2007 received from the European Patent Office. Applicants are submitting copies of the above-cited references as well as copies of the Search Reports. The relevance of the above-identified references has been described in the Supplementary Partial Search Reports.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no petition, certification or fee is required.

Respectfully submitted,




Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 7-80) PATENT AND TRADEMARK OFFICE

# LIST OF PRIOR ART CITED BY APPLICANT



Atty. Docket No. (Optional)

19781

Application Number

10/576,906

Applicant(s)

Angeline Ingrid Bartholomeusz, et al.

Filing Date

April 21, 2006

Group Art Unit

1645

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/94559 A1	12/13/01	PCT			✓	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chen W.N. et al., "Human Hepatitis B Virus Mutants: Significance of Molecular Changes", <i>FEBS Letters</i> 453(3):237-242 (1999), XP004259880
	Stuyver L.J. et al., "Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region", <i>Hepatology</i> 33(3):751-757 (2001), XP009029630
	Bartholomew M.M. et al., "Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection After Orthotopic Liver Transplant Ation", <i>Lancet</i> 349(9044):20-22 (1997), XP004843545
	Bartholomeusz A. et al., "Mutations in the Hepatitis B Virus Polymerase Gene that are Associated with Resistance to Famciclovir and Lamivudine", <i>International Antiviral News</i> 5(8):123-124 (1997), XP002044248
	Alestig E. et al., "Phylogenetic Origin of Hepatitis B Virus Strains with Precore C-1858 Variant", <i>Journal of Clinical Microbiology</i> 39(9):3200-3203 (2001), XP002419805
	Günther S. et al., "Analysis of Hepatitis B Virus Populations in an Interferon- $\alpha$ -Treated Patient Reveals Predominant Mutations in the C-Gene and Changing e-Antigenicity", <i>Virology</i> 244(1):146-160 (1998), XP004845022

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.